Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, yesterday hosted a virtual key opinion leader (KOL) event focused on the therapeutic landscape of Diabetic Macular Edema (DME), scientific rationale for an oral plasma kallikrein inhibitor (PKI) to target the disease, and the potential of RZ402, the company’s oral PKI, to change the standard of care as a safe, effective, and less invasive treatment option.
Related news for (RZLT)
- Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
- Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
- Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
- Rezolute, Inc. Announces Closing of Underwritten Offering